Posted by Michael Wonder on 17 Sep 2018
Patients with high-risk skin cancer have new treatment option
17 September 2018 - Hundreds of patients with a type of advanced skin cancer are set to benefit from a new treatment, dabrafenib plus trametinib.
NICE’s positive recommendation applies to adults who have stage III BRAF V600 mutation-positive melanoma that has spread to nearby lymph vessels or lymph glands, which make up an important part of our immune system.
Dabrafenib plus trametinib would be given to patients who have already had surgery to remove the tumour and associated lymph glands. Called adjuvant therapy or treatment, it aims to remove any residual cancer left behind.
